Sol-Gel Technologies (SLGL) Research & Development (2017 - 2026)
Sol-Gel Technologies (SLGL) posted quarterly Research & Development of $2.8 million for Q1 2026, down 68.49% year-over-year from $8.8 million in Q1 2025, and down 22.27% quarter-over-quarter from $3.6 million in Q4 2025.
Sol-Gel Technologies (SLGL) Research & Development (2017 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has reported Research & Development for 10 consecutive years, with $2.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development fell 68.49% year-over-year to $2.8 million; the TTM figure through Mar 2026 stood at $16.7 million (down 21.38% YoY), while the FY2025 annual figure was $22.8 million, up 28.09% from the prior year.
- Research & Development fell to $2.8 million in Q1 2026 per SLGL's latest filing, from $3.6 million in the prior quarter.
- Across five years, Research & Development topped out at $9.4 million in Q1 2023 and bottomed at $2.0 million in Q3 2022.
- Historically, Research & Development has averaged $4.7 million across 5 years, with a median of $4.6 million in 2025.
- Annual changes were most pronounced in 2023 — Research & Development surged 132.21% — and 2026, when it plunged 68.49%.
- Sol-Gel Technologies' Research & Development stood at $4.2 million in 2022, then dropped by 1.09% to $4.2 million in 2023, then advanced by 24.6% to $5.2 million in 2024, then sank by 31.04% to $3.6 million in 2025, then decreased by 22.27% to $2.8 million in 2026.
- Business Quant data shows SLGL's Research & Development at $2.8 million in Q1 2026, $3.6 million in Q4 2025, and $5.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Sol-Gel Technologies | 240.26 Mn | 230.12 Mn | - | 2.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.79 Mn |
| Dec 31, 2025 | 3.58 Mn |
| Sep 30, 2025 | 5.73 Mn |
| Jun 30, 2025 | 4.65 Mn |
| Mar 31, 2025 | 8.84 Mn |
| Dec 31, 2024 | 5.20 Mn |
| Sep 30, 2024 | 4.82 Mn |
| Jun 30, 2024 | 2.44 Mn |
| Mar 31, 2024 | 5.35 Mn |
| Dec 31, 2023 | 4.17 Mn |
| Sep 30, 2023 | 4.67 Mn |
| Jun 30, 2023 | 5.31 Mn |
| Mar 31, 2023 | 9.39 Mn |
| Dec 31, 2022 | 4.22 Mn |
| Sep 30, 2022 | 2.04 Mn |
| Jun 30, 2022 | 2.38 Mn |
| Mar 31, 2022 | 4.04 Mn |
| Dec 31, 2021 | 4.99 Mn |
| Sep 30, 2021 | 5.99 Mn |
| Jun 30, 2021 | 6.93 Mn |